Clinical Trials Logo
  1. Home
  2. T-Cell Lymphoma
  3. NCT01430013

Trial of Endostar Combined With CHOPT for T Cell Lymphoma

T Cell Lymphoma Clinical Trial

Official title:
Phase II Trial of Endostar Combined With CHOPT for T Cell Lymphoma

Clinical Trial Summary

To evaluate the efficacy and safety of Endostar combined with CHOPT in the treatment of T cell lymphoma.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01430013
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact
Status Active, not recruiting
Phase Phase 2
Start date June 2011
Completion date December 2015
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04653649 - CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. Phase 1/Phase 2
Not yet recruiting NCT06420076 - Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells Phase 1/Phase 2
Completed NCT01561833 - A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Phase 1
Withdrawn NCT04334174 - Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas Phase 2
Recruiting NCT05367856 - Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma Phase 2
Completed NCT00798096 - Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma Phase 2
Completed NCT03770000 - Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma Phase 1/Phase 2
Not yet recruiting NCT05996185 - Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma Phase 2
Active, not recruiting NCT04502446 - A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) Phase 1
Terminated NCT04973527 - LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Phase 1
Recruiting NCT05230680 - Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) Phase 1/Phase 2
Recruiting NCT03672084 - Allo-HSCT as First-line Consolidation in High-risk PTCL
Recruiting NCT05852028 - A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma
Enrolling by invitation NCT03628612 - Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified Phase 2
Recruiting NCT00974324 - Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma Phase 2
Completed NCT00877656 - HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma Phase 2/Phase 3
Not yet recruiting NCT05772728 - Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL) N/A
Completed NCT01300026 - AMG 319 Lymphoid Malignancy FIH Phase 1
Terminated NCT00880867 - Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma Phase 1
Recruiting NCT04840875 - Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma Phase 1